28 results on '"Stadtmauer, E. A."'
Search Results
2. Time from relapse after allogeneic stem cell transplantation (SCT) to donor leukocyte infusion (DLI) is longer, incidence of GVHD is higher, but survival is similar for recipients of unrelated DLI compared to matched sibling DLI.
3. Comparison of bortezomib- and lenalidomide-based therapies for the treatment of primary (AL) amyloidosis.
4. Dose-escalation trial of milatuzumab (humanized anti-CD74 monoclonal antibody) in multiple myeloma
5. Comparison of lenalidomide plus dexamethasone therapy used at first relapse versus later salvage therapy in relapsed or refractory multiple myeloma patients
6. Effect of bexarotene on platelet counts in patients undergoing cancer treatment: An analysis of clinical trials in lung cancer and leukemia
7. Post-transplant lymphoproliferative disorder in adult lung transplant recipients: A report on twenty-seven patients
8. Lenalidomide and stem cell collection in patients with multiple myeloma
9. Effect of rituximab (R) on clinical outcomes after autologous stem cell transplantation (ASCT) in pts with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
10. A two-arm prospective trial evaluating the ability of EBV PCR to diagnose and monitor posttransplant lymphoproliferative disorder
11. Outpatient autologous stem cell transplants for selected patients with myeloma: Morbidity, mortality, and duration of hospitalization
12. A phase I trial of bexarotene, a retinoid X receptor agonist, in non-M3 acute myeloid leukemia
13. Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): Results of a North American phase III study (MM-009)
14. Reproducibility of the Penn predictive score of tumor lysis syndrome (PPS-TLS) in acute myelogenous leukemia (AML)
15. Bortezomib is active in Waldenstrom’s Macroglobulinemia (WM)—Results of a National Cancer Institute of Canada (NCIC) phase II study in previously untreated or treated WM
16. Impact of prior autologous stem cell transplant (ASCT) in patients receiving bortezomib or dexamethasone for relapsed/refractory multiple myeloma in the APEX trial
17. Serum LDH predicts response rate, response duration, and survival of patients (pts) with relapsed/refractory non-Hodgkin’s lymphoma (NHL) treated with 131I-tositumomab (131I-Tab) or 90Y ibritumomab tiuxetan (90Y-Iab) radioimmunotherapy (RIT)
18. Lenalidomide (Len) in combination with dexamethasone (Dex) is more effective than Dex alone at first relapse and provides better outcomes when used early rather than as later salvage therapy in relapsed multiple myeloma (MM)
19. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed myeloma
20. Co-stimulated autologous T-cell infusion after autologous stem cell transplantation (SCT) for myeloma accelerates lymphocyte recovery and augments response to pneumoccal vaccine: Results of a randomized trial
21. Bortezomib appears to overcome poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials
22. Bortezomib in patients with relapsed or refractory mantle cell lymphoma (MCL): Preliminary results of the PINNACLE study
23. Bortezomib vs. dexamethasone in relapsed multiple myeloma: A phase 3 randomized study
24. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America.
25. Phase I/II study of combined granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor administration for the mobilization of hematopoietic progenitor cells.
26. Autologous bone marrow transplant in acute myeloid leukemia in first remission.
27. High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Cooperative Oncology Group protocol.
28. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.